Regional Meetings 2019

Visiting Professors: Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer — An Interactive Grand Rounds Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on PARP inhibition in the management of ovarian cancer. Each session in this regional series will feature a blend of didactic presentation, interactive polling of attendees using keypad devices and follow-up audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services Department at or call (800) 233-6153.

Learn about our other interactive Grand Rounds CME series:

Schedule of Events:

Friday, May 24, 2019
7:30 AM – 8:30 AM
Education program

Robert L Coleman, MD
Whittingham Cancer Center–Western Connecticut Health Network
Norwalk, Connecticut

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Thursday, June 13, 2019
12:00 PM – 1:00 PM
Education program

Robert L Coleman, MD
Valley-Mount Sinai Comprehensive Cancer Care
Paramus, New Jersey

Buffet lunch will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
Tuesday, September 17, 2019
8:00 AM – 9:00 AM
Education program

Ursula Matulonis, MD
Lenox Hill Hospital
New York, New York

Continental breakfast will be provided
Registration is open only to oncology professionals from this institution and invited guests.

Email us for more information.
There is no registration fee for these events. However, preregistration is advised as seating is limited.

Each 1-hour session will include 4 topic modules focused on the use of PARP inhibitors in the current management of ovarian cancer (OC) in addition to emerging research information on novel strategies under active investigation. Each event will employ an identical format that will include the following elements:

  • Discussion of Steering Committee Members’ Treatment Recommendations
  • Review of Available Clinical Research Findings
  • Integration of Interactive Audience Polling Results
MODULE 1 PARP Inhibitors in the Management of Newly Diagnosed OC; Genetic Drivers of OC Development and Current Testing Algorithms MODULE 2 Role of PARP Inhibition in the Management of Recurrent OC MODULE 3 Prevention, Recognition and Management of PARP Inhibitor Side Effects MODULE 4 Investigational Applications of Approved PARP Inhibitors; Novel PARP Inhibitors in Clinical Development

Each session will conclude with a 5-minute Q&A segment


Michael J Birrer, MD, PhD
Director, O’Neal Comprehensive Cancer Center
Professor of Medicine/Hematology and Oncology
Evalina B Spencer Chair in Oncology
The University of Alabama at Birmingham
Birmingham, Alabama

Robert L Coleman, MD
Professor and Vice Chair
Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Gottfried E Konecny, MD
Division of Hematology-Oncology
Department of Medicine David Geffen School of Medicine
UCLA Medical Center
Santa Monica, California

Ursula Matulonis, MD
Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Kathleen Moore, MD
Jim and Christy Everest Endowed
Chair in Cancer Research
Associate Director, Clinical Research
Director, Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma

David M O’Malley, MD
Medical Director
Gynecologic Oncology
Director, Clinical Research, Gynecologic Oncology
Co-Director, Gyn Oncology Phase I Program
ORIEN Physician Liaison for OSUCCC – James
The Ohio State University and The James Cancer Center
Columbus, Ohio

Angeles Alvarez Secord, MD, MHSc
Division of Gynecologic Oncology
Director of Gynecologic Oncology Clinical Trials
Associate Director of Clinical Research
Gynecology Oncology
Duke Cancer Institute
Duke University Medical Center
Durham, North Carolina

Robert M Wenham, MD, MS
Chair and Director of Research
Department of Gynecologic Oncology
Senior Member, Program of Chemical Biology and Molecular Medicine
Professor, Department of Interdisciplinary Oncology, USF
Moffitt Cancer Center
Tampa, Florida

Project Chair

Neil Love, MD
Research To Practice
Miami, Florida

Target Audience:
This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer (OC).

Learning Objectives:

  • Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing in OC, and use the results of these assessments to guide long-term treatment planning, including clinical trial accrual.
  • Recognize the recent FDA approval of olaparib as maintenance therapy for patients with advanced OC with a BRCA mutation after first-line platinum-based chemotherapy, and consider how the availability of this strategy affects current therapeutic algorithms.
  • Appreciate available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for patients with OC to effectively integrate these agents into routine clinical practice.
  • Consider published research findings with PARP inhibitors as maintenance therapy for patients with recurrent, platinum-sensitive OC, and develop strategies to identify appropriate candidates for this approach.
  • Recognize the toxicities associated with PARP inhibitors commonly used in the treatment of OC, and offer supportive management strategies to minimize and/or ameliorate these side effects.
  • Recall the biologic rationale for and ongoing research efforts evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy or immunotherapy, and refer appropriate and interested patients for clinical trial participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Clovis Oncology and Tesaro.